Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
AK044510
| |
AK044510 |
adult retina cDNA, RIKEN full-length enriched library, clone:A930017M14 product:laminin, alpha 1, full insert sequence. [AK044510] |
KLA | .96 |
1.07 |
1.03 |
1.05 |
1.00 |
1.06 |
1.16 |
| ATP | 1.04 |
1.04 |
1.04 |
1.04 |
1.05 |
1.08 |
1.01 |
| KLA/ATP | .96 |
1.08 |
1.07 |
1.10 |
1.12 |
1.08 |
1.01 |
|
Akt1 | |
NM_009652 |
thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] |
KLA | .80 |
.80 |
.75 |
.75 |
.71 |
.70 |
.82 |
| ATP | 1.00 |
1.02 |
.76 |
.85 |
.76 |
.68 |
.84 |
| KLA/ATP | .82 |
.80 |
.64 |
.68 |
.67 |
.61 |
.72 |
|
Akt2 | |
NM_007434 |
thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] |
KLA | 1.45 |
1.49 |
1.81 |
1.61 |
1.83 |
1.17 |
.92 |
| ATP | 1.12 |
1.12 |
1.00 |
1.28 |
1.20 |
.94 |
1.06 |
| KLA/ATP | 1.48 |
1.70 |
1.69 |
1.58 |
1.57 |
1.32 |
1.27 |
|
Akt3 | |
NM_011785 |
thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] |
KLA | 3.42 |
3.45 |
5.31 |
5.16 |
4.65 |
3.80 |
2.12 |
| ATP | 1.12 |
1.22 |
1.10 |
1.37 |
1.02 |
1.11 |
1.56 |
| KLA/ATP | 3.72 |
4.17 |
4.62 |
4.64 |
2.74 |
2.05 |
3.82 |
|
Alox5 | |
NM_009662 |
arachidonate 5-lipoxygenase (Alox5), mRNA [NM_009662] |
KLA | .83 |
.87 |
.88 |
.87 |
.71 |
.58 |
.21 |
| ATP | 1.03 |
1.03 |
1.14 |
1.21 |
.93 |
.55 |
.41 |
| KLA/ATP | .86 |
.85 |
.90 |
.97 |
.84 |
.61 |
.24 |
|
BB229853
| |
BB229853 |
gb|BB229853 RIKEN full-length enriched, 3 days neonate thymus Mus musculus cDNA clone A630023O21 3. [BB229853] |
KLA | 6.32 |
5.94 |
6.13 |
6.41 |
7.39 |
12.33 |
6.08 |
| ATP | .39 |
.24 |
.33 |
.38 |
1.18 |
5.75 |
2.85 |
| KLA/ATP | 2.27 |
2.02 |
3.25 |
4.04 |
7.11 |
10.22 |
13.93 |
|
Bad | |
AK029400 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] |
KLA | 1.15 |
1.22 |
1.26 |
1.31 |
1.40 |
1.67 |
1.59 |
| ATP | .95 |
1.06 |
1.12 |
1.06 |
.78 |
.89 |
1.27 |
| KLA/ATP | 1.25 |
1.39 |
1.33 |
1.29 |
1.11 |
.91 |
1.38 |
|
Bcl2 | |
NM_009741 |
B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 1, mRNA [NM_009741] |
KLA | .30 |
.26 |
.25 |
.25 |
.34 |
.38 |
.26 |
| ATP | .97 |
.89 |
1.50 |
1.04 |
.99 |
.29 |
.52 |
| KLA/ATP | .28 |
.26 |
.40 |
.33 |
.62 |
.29 |
.12 |
|
Bcl2 | |
NM_177410 |
B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 2, mRNA [NM_177410] |
KLA | .33 |
.33 |
.37 |
.42 |
.49 |
.46 |
.39 |
| ATP | 1.07 |
1.12 |
1.22 |
1.56 |
1.00 |
.38 |
.76 |
| KLA/ATP | .35 |
.34 |
.54 |
.89 |
.76 |
.36 |
.23 |
|
Bcl2l1 | |
NM_009743 |
Bcl2-like 1 (Bcl2l1), nuclear gene encoding mitochondrial protein, mRNA [NM_009743] |
KLA | .99 |
1.02 |
1.10 |
1.16 |
1.27 |
.97 |
1.05 |
| ATP | 1.18 |
1.42 |
.81 |
1.26 |
1.51 |
.71 |
1.67 |
| KLA/ATP | 1.21 |
1.30 |
.66 |
1.15 |
1.31 |
1.17 |
1.59 |
|
Birc2 | |
NM_007465 |
baculoviral IAP repeat-containing 2 (Birc2), mRNA [NM_007465] |
KLA | 4.63 |
4.59 |
3.77 |
2.79 |
2.32 |
2.07 |
1.84 |
| ATP | .95 |
.88 |
.84 |
.92 |
.76 |
1.34 |
1.28 |
| KLA/ATP | 4.70 |
4.93 |
4.13 |
2.60 |
1.34 |
1.60 |
2.31 |
|
Birc3 | |
BC011338 |
baculoviral IAP repeat-containing 3, mRNA (cDNA clone MGC:18386 IMAGE:3661563), complete cds [BC011338] |
KLA | 5.48 |
5.46 |
4.94 |
4.16 |
4.91 |
3.36 |
3.74 |
| ATP | 1.05 |
1.08 |
4.21 |
4.28 |
2.59 |
2.55 |
1.57 |
| KLA/ATP | 6.78 |
8.91 |
11.01 |
4.87 |
2.28 |
2.12 |
3.66 |
|
Birc3 | |
NM_007464 |
baculoviral IAP repeat-containing 3 (Birc3), mRNA [NM_007464] |
KLA | 17.83 |
15.88 |
13.48 |
11.14 |
11.79 |
6.90 |
6.10 |
| ATP | 1.14 |
1.16 |
1.70 |
4.07 |
5.00 |
6.33 |
2.41 |
| KLA/ATP | 14.77 |
16.44 |
19.09 |
13.91 |
8.27 |
6.22 |
7.73 |
|
Birc7 | |
AK053463 |
0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130019N06 product:weakly similar to BA261N11.1.3 (BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 7 (LIVIN), ISOFORM 3) (FRAGMENT) [Homo sapiens], full insert sequence [AK05 |
KLA | 1.02 |
1.02 |
.93 |
1.01 |
.91 |
1.27 |
1.07 |
| ATP | 1.02 |
1.03 |
.99 |
.93 |
.96 |
.98 |
1.01 |
| KLA/ATP | 1.00 |
1.04 |
.97 |
.94 |
.91 |
.93 |
.92 |
|
Casp3 | |
NM_009810 |
caspase 3 (Casp3), mRNA [NM_009810] |
KLA | 1.66 |
1.94 |
2.47 |
2.61 |
3.01 |
2.96 |
1.44 |
| ATP | .90 |
.99 |
1.17 |
1.30 |
1.01 |
1.17 |
.86 |
| KLA/ATP | 1.55 |
1.87 |
2.40 |
2.35 |
2.27 |
2.84 |
2.52 |
|
Casp3 | |
U49929 |
ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] |
KLA | 1.71 |
1.87 |
2.69 |
3.11 |
3.64 |
3.42 |
1.52 |
| ATP | 1.04 |
1.07 |
1.16 |
1.34 |
.98 |
1.27 |
.86 |
| KLA/ATP | 1.80 |
1.96 |
2.46 |
2.91 |
2.50 |
3.24 |
3.10 |
|
Casp8 | |
NM_009812 |
caspase 8 (Casp8), transcript variant 1, mRNA [NM_009812] |
KLA | 2.41 |
2.53 |
3.20 |
3.26 |
2.75 |
2.78 |
1.57 |
| ATP | .91 |
.96 |
.66 |
.67 |
.54 |
1.53 |
1.52 |
| KLA/ATP | 2.47 |
2.52 |
2.08 |
2.41 |
1.41 |
2.50 |
2.77 |
|
Casp9 | |
NM_015733 |
caspase 9 (Casp9), mRNA [NM_015733] |
KLA | .31 |
.31 |
.40 |
.66 |
.89 |
1.19 |
.91 |
| ATP | .88 |
.77 |
.91 |
.59 |
.43 |
.75 |
.93 |
| KLA/ATP | .26 |
.26 |
.30 |
.28 |
.80 |
1.06 |
.97 |
|
Ccr5 | |
NM_009917 |
chemokine (C-C motif) receptor 5 (Ccr5), mRNA [NM_009917] |
KLA | .92 |
.90 |
1.34 |
1.58 |
1.78 |
1.69 |
2.02 |
| ATP | 1.09 |
1.04 |
1.14 |
1.01 |
.71 |
.62 |
1.40 |
| KLA/ATP | .96 |
.98 |
1.28 |
1.29 |
1.04 |
.67 |
1.57 |
|
Cd40 | |
NM_170701 |
CD40 antigen (Cd40), transcript variant 3, mRNA [NM_170701] |
KLA | 23.87 |
23.62 |
23.26 |
23.98 |
22.07 |
17.37 |
5.34 |
| ATP | 1.00 |
1.01 |
1.06 |
2.96 |
2.65 |
3.03 |
1.70 |
| KLA/ATP | 22.77 |
23.79 |
29.67 |
28.85 |
28.08 |
21.62 |
13.02 |
|
Cd40lg | |
NM_011616 |
CD40 ligand (Cd40lg), mRNA [NM_011616] |
KLA | 1.03 |
1.07 |
1.02 |
.98 |
1.06 |
1.06 |
1.03 |
| ATP | .95 |
.92 |
.99 |
1.06 |
1.02 |
1.04 |
1.07 |
| KLA/ATP | 1.00 |
1.01 |
.93 |
1.04 |
.94 |
1.01 |
.98 |
|
Chuk | |
NM_007700 |
conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] |
KLA | 1.32 |
1.42 |
1.41 |
1.17 |
1.32 |
1.22 |
1.40 |
| ATP | 1.22 |
1.30 |
1.18 |
.97 |
1.02 |
1.00 |
1.37 |
| KLA/ATP | 1.56 |
1.61 |
1.21 |
1.09 |
.83 |
.84 |
1.17 |
|
Ciita | |
NM_007575 |
class II transactivator (Ciita), mRNA [NM_007575] |
KLA | 2.13 |
2.12 |
2.35 |
2.22 |
1.91 |
1.44 |
1.12 |
| ATP | 1.04 |
1.04 |
1.17 |
1.17 |
1.61 |
1.15 |
1.21 |
| KLA/ATP | 2.23 |
2.44 |
1.88 |
1.76 |
1.64 |
1.14 |
1.52 |
|
Cycs | |
NM_007808 |
cytochrome c, somatic (Cycs), nuclear gene encoding mitochondrial protein, mRNA [NM_007808] |
KLA | 2.20 |
2.21 |
2.35 |
2.69 |
2.62 |
3.22 |
2.14 |
| ATP | .87 |
.89 |
1.31 |
1.05 |
1.06 |
1.20 |
1.26 |
| KLA/ATP | 1.88 |
2.04 |
2.86 |
2.26 |
2.57 |
2.45 |
2.03 |
|
Cyct | |
NM_009989 |
cytochrome c, testis (Cyct), mRNA [NM_009989] |
KLA | .93 |
1.01 |
1.00 |
.99 |
1.02 |
1.03 |
.96 |
| ATP | 1.01 |
.91 |
1.01 |
.99 |
.98 |
.95 |
.95 |
| KLA/ATP | 1.10 |
.96 |
.89 |
.89 |
1.10 |
1.05 |
.97 |
|
Gnai1 | |
NM_010305 |
guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305] |
KLA | .95 |
1.01 |
1.01 |
1.00 |
1.09 |
1.10 |
1.08 |
| ATP | 1.06 |
1.06 |
.99 |
1.15 |
1.02 |
.94 |
.99 |
| KLA/ATP | 1.02 |
1.04 |
.99 |
1.16 |
1.01 |
1.02 |
1.13 |
|
Gnai2 | |
NM_008138 |
guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138] |
KLA | .74 |
.79 |
.82 |
.74 |
.91 |
.97 |
1.10 |
| ATP | 1.07 |
1.16 |
.78 |
1.12 |
.78 |
.48 |
.82 |
| KLA/ATP | .91 |
.81 |
.53 |
.80 |
.60 |
.68 |
.87 |
|
Gnai3 | |
NM_010306 |
guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306] |
KLA | 1.23 |
1.24 |
1.14 |
1.06 |
.99 |
1.15 |
1.09 |
| ATP | .96 |
.93 |
.86 |
.64 |
1.34 |
2.02 |
1.35 |
| KLA/ATP | 1.20 |
1.24 |
.97 |
.76 |
1.21 |
1.62 |
1.17 |
|
Gnao1 | |
NM_001113384 |
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant B, mRNA [NM_001113384] |
KLA | .95 |
.98 |
1.03 |
1.00 |
1.02 |
1.02 |
.99 |
| ATP | .95 |
1.02 |
1.01 |
1.08 |
.99 |
.97 |
.95 |
| KLA/ATP | 1.05 |
1.04 |
1.10 |
.99 |
1.01 |
.98 |
1.03 |
|
Gnao1 | |
NM_010308 |
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant A, mRNA [NM_010308] |
KLA | .98 |
.96 |
1.00 |
.97 |
.96 |
.97 |
1.01 |
| ATP | 1.12 |
.99 |
1.05 |
.87 |
.97 |
1.02 |
1.01 |
| KLA/ATP | .93 |
1.00 |
.99 |
1.01 |
1.05 |
1.07 |
.98 |
|
H2-Aa | |
NM_010378 |
histocompatibility 2, class II antigen A, alpha (H2-Aa), mRNA [NM_010378] |
KLA | 1.43 |
1.59 |
1.68 |
1.50 |
1.62 |
1.89 |
1.64 |
| ATP | 1.07 |
1.15 |
1.27 |
1.90 |
1.92 |
1.77 |
1.55 |
| KLA/ATP | 1.62 |
1.81 |
1.74 |
2.29 |
1.89 |
1.92 |
2.19 |
|
H2-Ab1 | |
BC010322 |
histocompatibility 2, class II antigen A, beta 1, mRNA (cDNA clone MGC:6297 IMAGE:2651058), complete cds [BC010322] |
KLA | 1.73 |
1.76 |
1.77 |
1.55 |
1.95 |
2.10 |
2.27 |
| ATP | 1.03 |
1.18 |
1.32 |
1.99 |
1.79 |
1.56 |
1.61 |
| KLA/ATP | 1.70 |
2.01 |
1.74 |
2.52 |
1.58 |
2.01 |
2.75 |
|
H2-Ab1 | |
NM_207105 |
histocompatibility 2, class II antigen A, beta 1 (H2-Ab1), mRNA [NM_207105] |
KLA | 2.02 |
2.15 |
2.07 |
2.09 |
2.32 |
2.78 |
3.08 |
| ATP | 1.11 |
1.20 |
1.42 |
2.33 |
2.33 |
2.25 |
1.87 |
| KLA/ATP | 2.11 |
2.32 |
2.52 |
3.62 |
2.67 |
2.96 |
5.04 |
|
H2-DMa | |
NM_010386 |
histocompatibility 2, class II, locus DMa (H2-DMa), mRNA [NM_010386] |
KLA | 1.49 |
1.50 |
1.65 |
1.65 |
1.91 |
2.23 |
1.69 |
| ATP | 1.04 |
1.12 |
1.26 |
1.67 |
1.24 |
.99 |
1.32 |
| KLA/ATP | 1.58 |
1.68 |
1.70 |
2.02 |
1.37 |
1.35 |
1.90 |
|
H2-DMb1 | |
NM_010387 |
histocompatibility 2, class II, locus Mb1 (H2-DMb1), mRNA [NM_010387] |
KLA | 1.06 |
1.14 |
1.08 |
1.13 |
1.24 |
1.41 |
1.37 |
| ATP | 1.01 |
1.02 |
1.09 |
1.14 |
.92 |
.73 |
1.36 |
| KLA/ATP | 1.13 |
1.05 |
1.21 |
1.17 |
.98 |
.83 |
1.41 |
|
H2-DMb2 | |
NM_010388 |
histocompatibility 2, class II, locus Mb2 (H2-DMb2), mRNA [NM_010388] |
KLA | 1.00 |
1.04 |
.93 |
.95 |
.96 |
.95 |
1.03 |
| ATP | 1.06 |
1.04 |
.94 |
.92 |
.97 |
.95 |
1.00 |
| KLA/ATP | .90 |
.94 |
.99 |
.94 |
.90 |
.96 |
.92 |
|
H2-Eb1 | |
X52641 |
gb|Mouse mRNA for I-A beta NOD. [X52641] |
KLA | 1.94 |
2.06 |
1.94 |
1.87 |
1.96 |
2.18 |
1.76 |
| ATP | 1.11 |
1.20 |
1.53 |
2.70 |
3.02 |
2.91 |
1.40 |
| KLA/ATP | 2.09 |
2.11 |
2.26 |
3.55 |
2.76 |
3.05 |
3.05 |
|
H2-Oa | |
NM_008206 |
histocompatibility 2, O region alpha locus (H2-Oa), mRNA [NM_008206] |
KLA | 1.22 |
1.32 |
1.37 |
1.33 |
1.31 |
1.26 |
1.53 |
| ATP | 1.02 |
1.05 |
1.16 |
1.21 |
1.12 |
1.07 |
1.16 |
| KLA/ATP | 1.32 |
1.34 |
1.31 |
1.34 |
1.25 |
1.35 |
2.78 |
|
H2-Ob | |
NM_010389 |
histocompatibility 2, O region beta locus (H2-Ob), mRNA [NM_010389] |
KLA | 1.05 |
1.07 |
1.01 |
.96 |
1.10 |
1.02 |
1.00 |
| ATP | 1.04 |
.99 |
1.00 |
1.03 |
.94 |
1.07 |
.94 |
| KLA/ATP | 1.02 |
.97 |
1.06 |
1.08 |
1.00 |
.96 |
1.05 |
|
Hspa1a | |
NM_010479 |
heat shock protein 1A (Hspa1a), mRNA [NM_010479] |
KLA | 7.88 |
6.99 |
4.47 |
5.18 |
7.81 |
11.47 |
4.14 |
| ATP | 1.88 |
5.62 |
43.42 |
58.76 |
55.53 |
28.89 |
9.13 |
| KLA/ATP | 7.40 |
7.62 |
28.23 |
54.12 |
70.14 |
43.09 |
22.49 |
|
Hspa1b | |
NM_010478 |
heat shock protein 1B (Hspa1b), mRNA [NM_010478] |
KLA | 5.01 |
4.73 |
3.77 |
3.62 |
4.81 |
6.53 |
3.12 |
| ATP | 1.34 |
3.07 |
14.11 |
17.14 |
17.51 |
11.21 |
4.82 |
| KLA/ATP | 5.04 |
5.15 |
11.63 |
19.94 |
20.84 |
15.79 |
9.30 |
|
Hspa1l | |
NM_013558 |
heat shock protein 1-like (Hspa1l), mRNA [NM_013558] |
KLA | .98 |
1.04 |
1.10 |
1.21 |
1.51 |
1.97 |
1.86 |
| ATP | 1.03 |
1.08 |
1.07 |
1.14 |
.93 |
1.21 |
1.89 |
| KLA/ATP | 1.06 |
1.01 |
.99 |
1.09 |
.97 |
1.39 |
2.87 |
|
Hspa2 | |
NM_008301 |
heat shock protein 2 (Hspa2), transcript variant 1, mRNA [NM_008301] |
KLA | .98 |
.97 |
1.12 |
1.23 |
1.20 |
1.72 |
1.38 |
| ATP | 1.01 |
1.10 |
1.45 |
3.12 |
2.45 |
1.98 |
.98 |
| KLA/ATP | .99 |
1.12 |
1.52 |
2.60 |
2.89 |
2.62 |
1.18 |
|
Hspa8 | |
NM_031165 |
heat shock protein 8 (Hspa8), mRNA [NM_031165] |
KLA | 1.00 |
.98 |
1.27 |
1.18 |
1.45 |
1.60 |
1.31 |
| ATP | 1.22 |
1.18 |
1.07 |
1.44 |
1.07 |
.53 |
.57 |
| KLA/ATP | 1.18 |
1.22 |
1.14 |
1.08 |
.93 |
.82 |
.77 |
|
Ifng | |
NM_008337 |
interferon gamma (Ifng), mRNA [NM_008337] |
KLA | 1.05 |
1.02 |
1.01 |
1.01 |
1.01 |
1.04 |
1.00 |
| ATP | 1.00 |
1.01 |
1.01 |
.98 |
.97 |
1.04 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
1.06 |
1.10 |
1.24 |
1.10 |
1.04 |
|
Ifngr1 | |
NM_010511 |
interferon gamma receptor 1 (Ifngr1), mRNA [NM_010511] |
KLA | .81 |
.60 |
.37 |
.35 |
.34 |
.39 |
.54 |
| ATP | 1.05 |
.96 |
1.15 |
.97 |
.80 |
.67 |
.45 |
| KLA/ATP | .57 |
.57 |
.63 |
.36 |
.28 |
.33 |
.36 |
|
Ifngr2 | |
NM_008338 |
interferon gamma receptor 2 (Ifngr2), mRNA [NM_008338] |
KLA | 1.45 |
1.49 |
1.74 |
2.22 |
3.22 |
2.42 |
1.96 |
| ATP | 1.11 |
1.03 |
.81 |
.78 |
1.12 |
1.28 |
1.34 |
| KLA/ATP | 1.48 |
1.41 |
1.17 |
1.23 |
1.48 |
1.89 |
2.13 |
|
Igtp | |
NM_018738 |
interferon gamma induced GTPase (Igtp), mRNA [NM_018738] |
KLA | 26.41 |
24.55 |
23.14 |
22.50 |
15.55 |
19.44 |
9.85 |
| ATP | .96 |
.79 |
.86 |
.65 |
.84 |
12.01 |
6.81 |
| KLA/ATP | 24.01 |
22.61 |
23.56 |
18.27 |
20.74 |
31.37 |
38.87 |
|
Ikbkb | |
NM_010546 |
inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] |
KLA | 1.88 |
2.10 |
2.14 |
1.83 |
1.73 |
1.31 |
1.19 |
| ATP | .81 |
.74 |
.55 |
.49 |
.59 |
1.05 |
.96 |
| KLA/ATP | 1.86 |
1.73 |
1.39 |
1.12 |
.89 |
1.17 |
1.24 |
|
Ikbkg | |
AK042138 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] |
KLA | .92 |
.87 |
.78 |
.78 |
.87 |
.88 |
.62 |
| ATP | .84 |
.71 |
.80 |
.50 |
1.15 |
2.33 |
.61 |
| KLA/ATP | .72 |
.69 |
.74 |
.48 |
1.06 |
1.97 |
.68 |
|
Ikbkg | |
NM_010547 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] |
KLA | 1.51 |
1.63 |
1.74 |
1.83 |
1.83 |
1.73 |
1.72 |
| ATP | .80 |
.79 |
.82 |
.75 |
.66 |
2.58 |
2.37 |
| KLA/ATP | 1.43 |
1.42 |
1.17 |
1.04 |
.71 |
1.54 |
3.17 |
|
Ikbkg | |
NM_178590 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] |
KLA | .84 |
.93 |
.86 |
.91 |
1.03 |
.89 |
.88 |
| ATP | 1.03 |
.98 |
.68 |
.56 |
.51 |
.93 |
.68 |
| KLA/ATP | .89 |
.81 |
.55 |
.52 |
.41 |
.67 |
.65 |
|
Il10 | |
NM_010548 |
interleukin 10 (Il10), mRNA [NM_010548] |
KLA | 17.59 |
18.64 |
22.22 |
23.06 |
11.83 |
8.27 |
2.07 |
| ATP | 1.86 |
3.22 |
7.72 |
20.51 |
25.86 |
8.38 |
1.01 |
| KLA/ATP | 17.91 |
23.49 |
34.53 |
34.48 |
20.98 |
12.03 |
8.17 |
|
Il10ra | |
NM_008348 |
interleukin 10 receptor, alpha (Il10ra), mRNA [NM_008348] |
KLA | 4.92 |
4.49 |
5.29 |
3.79 |
4.00 |
3.02 |
1.77 |
| ATP | 1.15 |
1.13 |
1.19 |
1.16 |
2.95 |
1.73 |
.80 |
| KLA/ATP | 5.70 |
4.92 |
6.13 |
3.01 |
4.78 |
3.11 |
2.37 |
|
Il10rb | |
AF440787 |
C57BL [AF440787] |
KLA | .71 |
.67 |
.65 |
.81 |
1.20 |
1.50 |
1.07 |
| ATP | 1.03 |
1.04 |
1.01 |
1.12 |
.84 |
.85 |
1.52 |
| KLA/ATP | .67 |
.68 |
.70 |
.82 |
.92 |
1.23 |
1.83 |
|
Il10rb | |
AK018347 |
12 days embryo female ovary cDNA, RIKEN full-length enriched library, clone:6620401D04 product:unclassifiable, full insert sequence. [AK018347] |
KLA | .89 |
1.00 |
1.05 |
1.07 |
1.29 |
1.12 |
.96 |
| ATP | .91 |
.73 |
1.23 |
1.43 |
.98 |
1.06 |
.92 |
| KLA/ATP | .86 |
.83 |
1.13 |
1.41 |
1.24 |
1.11 |
1.13 |
|
Il12a | |
NM_008351 |
interleukin 12a (Il12a), mRNA [NM_008351] |
KLA | 2.37 |
2.47 |
2.17 |
1.49 |
1.46 |
1.12 |
1.20 |
| ATP | 1.01 |
.97 |
1.12 |
1.07 |
1.02 |
1.07 |
1.06 |
| KLA/ATP | 2.01 |
2.76 |
2.54 |
1.70 |
1.08 |
1.10 |
1.27 |
|
Il12b | |
NM_008352 |
interleukin 12b (Il12b), mRNA [NM_008352] |
KLA | 194.79 |
211.32 |
198.97 |
173.01 |
142.24 |
40.28 |
3.10 |
| ATP | 1.05 |
1.10 |
1.59 |
1.99 |
2.71 |
2.72 |
1.52 |
| KLA/ATP | 191.27 |
223.23 |
280.10 |
224.29 |
183.03 |
68.43 |
10.69 |
|
Irak1 | |
NM_008363 |
interleukin-1 receptor-associated kinase 1 (Irak1), mRNA [NM_008363] |
KLA | .67 |
.67 |
.64 |
.56 |
.58 |
.58 |
.84 |
| ATP | 1.02 |
1.10 |
.94 |
1.14 |
.81 |
.54 |
.87 |
| KLA/ATP | .72 |
.72 |
.57 |
.67 |
.51 |
.43 |
.62 |
|
Irak4 | |
NM_029926 |
interleukin-1 receptor-associated kinase 4 (Irak4), mRNA [NM_029926] |
KLA | .82 |
.86 |
.78 |
.82 |
.95 |
1.21 |
1.22 |
| ATP | 1.02 |
1.18 |
.95 |
1.10 |
.79 |
.85 |
.82 |
| KLA/ATP | .86 |
.89 |
.77 |
.90 |
.78 |
.96 |
.88 |
|
Irgm | |
AK083346 |
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:C920012B18 product:interferon inducible protein 1, full insert sequence. [AK083346] |
KLA | 1.25 |
1.33 |
1.25 |
1.13 |
1.12 |
1.24 |
1.02 |
| ATP | .99 |
.96 |
.88 |
.98 |
1.02 |
1.06 |
1.07 |
| KLA/ATP | 1.26 |
1.30 |
2.25 |
2.90 |
1.95 |
1.27 |
1.01 |
|
Irgm | |
NM_008326 |
immunity-related GTPase family, M (Irgm), mRNA [NM_008326] |
KLA | 10.25 |
9.21 |
9.70 |
8.29 |
7.43 |
6.77 |
5.34 |
| ATP | 1.10 |
1.02 |
.62 |
.64 |
1.16 |
5.44 |
5.65 |
| KLA/ATP | 10.63 |
10.70 |
8.12 |
10.56 |
10.42 |
12.63 |
15.07 |
|
Itga6 | |
BC024571 |
integrin alpha 6, mRNA (cDNA clone IMAGE:5036677). [BC024571] |
KLA | .44 |
.44 |
.37 |
.28 |
.25 |
.29 |
.34 |
| ATP | .96 |
1.01 |
.90 |
.58 |
.35 |
.11 |
.22 |
| KLA/ATP | .44 |
.41 |
.34 |
.23 |
.15 |
.09 |
.08 |
|
Itga6 | |
NM_008397 |
integrin alpha 6 (Itga6), mRNA [NM_008397] |
KLA | .57 |
.58 |
.51 |
.45 |
.43 |
.44 |
.47 |
| ATP | 1.05 |
1.12 |
.86 |
.90 |
.57 |
.27 |
.36 |
| KLA/ATP | .64 |
.67 |
.50 |
.57 |
.39 |
.29 |
.26 |
|
Itgb1 | |
NM_010578 |
integrin beta 1 (fibronectin receptor beta) (Itgb1), mRNA [NM_010578] |
KLA | 1.05 |
1.09 |
1.13 |
.92 |
1.01 |
.93 |
.88 |
| ATP | 1.14 |
1.30 |
.92 |
1.07 |
1.04 |
.83 |
.70 |
| KLA/ATP | 1.26 |
1.30 |
.87 |
1.02 |
.66 |
.65 |
.62 |
|
Itgb1 | |
U37029 |
integrin beta1D mRNA, partial cds. [U37029] |
KLA | .93 |
.95 |
.96 |
1.01 |
.97 |
1.01 |
.98 |
| ATP | 1.05 |
.99 |
.99 |
1.03 |
1.03 |
.97 |
.94 |
| KLA/ATP | .99 |
.98 |
1.04 |
.97 |
1.02 |
1.01 |
.99 |
|
Jak1 | |
AK029232 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831433J01 product:Janus kinase 1, full insert sequence. [AK029232] |
KLA | 1.25 |
1.13 |
1.19 |
1.31 |
1.24 |
1.17 |
1.14 |
| ATP | 1.01 |
1.11 |
.96 |
1.38 |
1.06 |
1.26 |
1.05 |
| KLA/ATP | 1.19 |
1.29 |
1.27 |
1.59 |
1.18 |
1.38 |
1.24 |
|
Jak1 | |
NM_146145 |
Janus kinase 1 (Jak1), mRNA [NM_146145] |
KLA | 1.71 |
1.75 |
1.79 |
1.81 |
1.72 |
1.37 |
1.21 |
| ATP | 1.03 |
1.01 |
.75 |
1.04 |
1.32 |
1.90 |
1.14 |
| KLA/ATP | 1.84 |
1.73 |
1.49 |
2.07 |
2.01 |
1.83 |
1.68 |
|
Jak2 | |
NM_008413 |
Janus kinase 2 (Jak2), transcript variant 1, mRNA [NM_008413] |
KLA | 14.86 |
15.05 |
15.42 |
14.15 |
11.46 |
8.81 |
5.47 |
| ATP | .99 |
1.06 |
1.09 |
1.43 |
2.83 |
4.71 |
1.62 |
| KLA/ATP | 13.77 |
14.74 |
14.94 |
12.97 |
7.53 |
9.34 |
9.17 |
|
Lama1 | |
NM_008480 |
laminin, alpha 1 (Lama1), mRNA [NM_008480] |
KLA | .99 |
1.04 |
.97 |
.96 |
1.01 |
.99 |
1.05 |
| ATP | 1.01 |
.99 |
.98 |
1.05 |
.99 |
1.09 |
.99 |
| KLA/ATP | 1.00 |
.97 |
.86 |
1.04 |
1.05 |
.99 |
1.00 |
|
Lama2 | |
AK046114 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230342M05 product:laminin, alpha 2, full insert sequence. [AK046114] |
KLA | 1.06 |
1.00 |
.95 |
1.10 |
1.04 |
.99 |
.96 |
| ATP | .98 |
1.09 |
1.00 |
.97 |
.96 |
1.12 |
1.01 |
| KLA/ATP | .94 |
1.04 |
1.05 |
1.00 |
.99 |
1.00 |
.98 |
|
Lama2 | |
NM_008481 |
laminin, alpha 2 (Lama2), mRNA [NM_008481] |
KLA | .96 |
.99 |
.96 |
1.02 |
.95 |
1.00 |
.97 |
| ATP | 1.05 |
1.00 |
1.01 |
.94 |
1.01 |
1.04 |
.96 |
| KLA/ATP | .99 |
1.04 |
1.06 |
1.10 |
.98 |
.95 |
.97 |
|
Lama2 | |
U12147 |
laminin-2 alpha2 chain mRNA, complete cds. [U12147] |
KLA | .96 |
1.00 |
.99 |
1.00 |
.98 |
1.02 |
1.03 |
| ATP | 1.01 |
.99 |
1.02 |
1.04 |
1.01 |
.99 |
1.02 |
| KLA/ATP | 1.00 |
1.01 |
1.00 |
1.01 |
.99 |
1.04 |
1.00 |
|
Lama3 | |
XM_140451 |
gb|PREDICTED: Mus musculus laminin, alpha 3, transcript variant 1 (Lama3), mRNA [XM_140451] |
KLA | .76 |
.75 |
.73 |
.75 |
.71 |
.74 |
.67 |
| ATP | 1.04 |
1.12 |
1.05 |
1.20 |
.88 |
.73 |
.78 |
| KLA/ATP | .77 |
.81 |
.78 |
.82 |
.78 |
.71 |
.70 |
|
Lama4 | |
NM_010681 |
laminin, alpha 4 (Lama4), mRNA [NM_010681] |
KLA | .99 |
.99 |
1.01 |
1.02 |
.98 |
.97 |
.96 |
| ATP | 1.00 |
1.08 |
1.05 |
1.05 |
1.03 |
1.04 |
.96 |
| KLA/ATP | 1.00 |
1.03 |
.93 |
1.00 |
.94 |
.90 |
.95 |
|
Lama5 | |
NM_001081171 |
laminin, alpha 5 (Lama5), mRNA [NM_001081171] |
KLA | 1.11 |
1.07 |
1.09 |
1.00 |
.96 |
1.00 |
1.01 |
| ATP | 1.01 |
.99 |
1.03 |
1.01 |
1.00 |
.99 |
.99 |
| KLA/ATP | 1.12 |
1.08 |
1.05 |
1.04 |
.99 |
1.09 |
1.04 |
|
Lamb1-1 | |
NM_008482 |
laminin B1 subunit 1 (Lamb1-1), mRNA [NM_008482] |
KLA | .93 |
.99 |
1.10 |
1.01 |
.95 |
1.00 |
.86 |
| ATP | .99 |
1.13 |
1.06 |
.99 |
1.07 |
.99 |
.97 |
| KLA/ATP | 1.00 |
1.06 |
.98 |
.95 |
.93 |
.89 |
1.04 |
|
Lamb2 | |
NM_008483 |
laminin, beta 2 (Lamb2), mRNA [NM_008483] |
KLA | .93 |
.90 |
.95 |
.81 |
.79 |
.58 |
.37 |
| ATP | 1.01 |
1.09 |
.95 |
.99 |
.80 |
.81 |
.38 |
| KLA/ATP | .96 |
.87 |
1.00 |
.91 |
.72 |
.60 |
.38 |
|
Lamb3 | |
NM_008484 |
laminin, beta 3 (Lamb3), mRNA [NM_008484] |
KLA | 1.00 |
.97 |
1.02 |
.98 |
1.00 |
1.04 |
.93 |
| ATP | 1.01 |
1.01 |
.91 |
.97 |
.89 |
1.04 |
1.03 |
| KLA/ATP | 1.00 |
.95 |
.97 |
1.00 |
.95 |
.87 |
1.02 |
|
Lamc1 | |
J03484 |
gb|Mouse laminin B2 chain mRNA, complete cds [J03484] |
KLA | 1.14 |
1.01 |
1.04 |
.87 |
.82 |
.63 |
.75 |
| ATP | .99 |
1.09 |
1.07 |
1.14 |
1.36 |
2.38 |
.66 |
| KLA/ATP | 1.04 |
1.10 |
.95 |
1.12 |
1.30 |
1.70 |
.68 |
|
Lamc2 | |
AF106279 |
laminin gamma2 chain mRNA, partial cds. [AF106279] |
KLA | 1.03 |
1.04 |
1.03 |
1.09 |
.97 |
.97 |
.98 |
| ATP | 1.04 |
1.04 |
1.16 |
1.48 |
1.46 |
1.29 |
1.26 |
| KLA/ATP | 1.04 |
1.00 |
1.03 |
1.06 |
.95 |
.99 |
1.08 |
|
Lamc2 | |
NM_008485 |
laminin, gamma 2 (Lamc2), mRNA [NM_008485] |
KLA | 1.16 |
1.22 |
1.23 |
1.07 |
1.04 |
1.12 |
1.04 |
| ATP | 1.01 |
1.10 |
2.81 |
4.58 |
4.35 |
3.34 |
2.36 |
| KLA/ATP | 1.31 |
1.29 |
1.41 |
1.40 |
1.28 |
1.25 |
1.49 |
|
Lamc3 | |
AF083372 |
laminin 12 gamma 3 chain mRNA, complete cds. [AF083372] |
KLA | .96 |
.94 |
.99 |
.96 |
.94 |
1.02 |
.88 |
| ATP | 1.06 |
1.00 |
.95 |
.98 |
.98 |
.99 |
1.02 |
| KLA/ATP | .90 |
.98 |
1.03 |
.95 |
.88 |
.97 |
.96 |
|
Lamc3 | |
NM_011836 |
laminin gamma 3 (Lamc3), mRNA [NM_011836] |
KLA | 1.00 |
1.00 |
1.04 |
1.04 |
1.03 |
1.01 |
.97 |
| ATP | .99 |
1.06 |
1.00 |
.91 |
.98 |
.96 |
1.01 |
| KLA/ATP | .98 |
1.04 |
1.01 |
1.02 |
.96 |
.95 |
.98 |
|
Ldlr | |
NM_010700 |
low density lipoprotein receptor (Ldlr), mRNA [NM_010700] |
KLA | 2.17 |
2.00 |
2.07 |
1.87 |
1.38 |
.78 |
1.00 |
| ATP | .98 |
.87 |
1.53 |
1.14 |
1.01 |
1.52 |
1.60 |
| KLA/ATP | 1.86 |
1.76 |
2.52 |
1.55 |
1.59 |
.84 |
.82 |
|
Ldlr | |
Z19521 |
gb|M.musculus Ldlr mRNA encoding low density lipoprotein receptor. [Z19521] |
KLA | 1.94 |
1.93 |
2.24 |
2.01 |
1.73 |
1.08 |
1.26 |
| ATP | 1.12 |
1.21 |
1.47 |
1.65 |
1.28 |
1.45 |
1.67 |
| KLA/ATP | 2.22 |
2.28 |
2.17 |
2.27 |
1.50 |
1.13 |
1.29 |
|
Ly96 | |
NM_016923 |
lymphocyte antigen 96 (Ly96), mRNA [NM_016923] |
KLA | 2.25 |
2.07 |
2.39 |
2.38 |
2.38 |
2.30 |
2.14 |
| ATP | 1.19 |
1.02 |
1.35 |
1.20 |
1.69 |
2.83 |
1.93 |
| KLA/ATP | 2.36 |
2.28 |
3.07 |
2.62 |
2.68 |
2.34 |
3.13 |
|
Map2k3 | |
NM_008928 |
mitogen-activated protein kinase kinase 3 (Map2k3), mRNA [NM_008928] |
KLA | .88 |
.88 |
.73 |
.65 |
.99 |
1.34 |
.92 |
| ATP | 1.04 |
1.09 |
.89 |
1.62 |
1.93 |
1.75 |
1.17 |
| KLA/ATP | 1.00 |
.92 |
.66 |
1.21 |
1.80 |
2.24 |
2.10 |
|
Map2k6 | |
NM_011943 |
mitogen-activated protein kinase kinase 6 (Map2k6), mRNA [NM_011943] |
KLA | .68 |
.67 |
.64 |
.67 |
.62 |
.59 |
.61 |
| ATP | 1.02 |
1.12 |
1.04 |
1.10 |
.79 |
.61 |
.61 |
| KLA/ATP | .73 |
.69 |
.71 |
.74 |
.66 |
.62 |
.98 |
|
Map3k7 | |
NM_172688 |
mitogen-activated protein kinase kinase kinase 7 (Map3k7), mRNA [NM_172688] |
KLA | 1.48 |
1.49 |
1.51 |
1.24 |
1.21 |
1.19 |
1.61 |
| ATP | 1.10 |
1.16 |
1.03 |
1.03 |
1.12 |
1.61 |
1.61 |
| KLA/ATP | 1.43 |
1.56 |
1.05 |
1.15 |
.85 |
1.48 |
1.76 |
|
Map3k7ip 1 | |
NM_025609 |
mitogen-activated protein kinase kinase kinase 7 interacting protein 1 (Map3k7ip1), mRNA [NM_025609] |
KLA | .32 |
.30 |
.35 |
.56 |
.67 |
.82 |
.76 |
| ATP | .95 |
.81 |
.80 |
.42 |
.35 |
.40 |
.80 |
| KLA/ATP | .33 |
.30 |
.37 |
.20 |
.45 |
.62 |
.65 |
|
Map3k7ip 2 | |
AK086230 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930015C19 product:inferred: Mus musculus, Similar to TAK1-binding protein 2; KIAA0733 protein, clone MGC:8010 IMAGE:3586132, mRNA, complete cds, full insert sequence. [A |
KLA | 1.14 |
1.02 |
1.07 |
1.03 |
1.13 |
1.02 |
.96 |
| ATP | 1.00 |
.88 |
.92 |
.90 |
1.06 |
.96 |
.94 |
| KLA/ATP | 1.05 |
1.00 |
.90 |
.98 |
1.02 |
.97 |
.97 |
|
Map3k7ip 2 | |
NM_138667 |
mitogen-activated protein kinase kinase kinase 7 interacting protein 2 (Map3k7ip2), mRNA [NM_138667] |
KLA | 3.43 |
3.22 |
3.19 |
2.41 |
2.13 |
1.51 |
1.10 |
| ATP | 1.08 |
1.08 |
.86 |
.81 |
1.30 |
1.32 |
1.02 |
| KLA/ATP | 3.34 |
3.66 |
3.00 |
2.58 |
1.80 |
1.52 |
1.61 |
|
Mapk1 | |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
Mapk1 | |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
Mapk10 | |
AK076990 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] |
KLA | 1.03 |
1.05 |
.98 |
1.04 |
.94 |
.95 |
1.02 |
| ATP | 1.00 |
.99 |
1.06 |
.97 |
1.01 |
.96 |
.99 |
| KLA/ATP | 1.07 |
1.01 |
.95 |
1.05 |
.82 |
.95 |
.87 |
|
Mapk10 | |
NM_009158 |
mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] |
KLA | .95 |
1.00 |
.97 |
1.01 |
.99 |
1.01 |
.95 |
| ATP | 1.01 |
1.02 |
.98 |
1.01 |
1.04 |
1.01 |
.99 |
| KLA/ATP | 1.05 |
.99 |
1.01 |
.98 |
.92 |
.97 |
.98 |
|
Mapk11 | |
NM_011161 |
mitogen-activated protein kinase 11 (Mapk11), mRNA [NM_011161] |
KLA | 1.28 |
1.30 |
1.41 |
1.46 |
1.58 |
1.29 |
.98 |
| ATP | .96 |
.95 |
.89 |
.82 |
.79 |
1.09 |
.85 |
| KLA/ATP | 1.44 |
1.42 |
1.32 |
1.23 |
1.23 |
.74 |
.66 |
|
Mapk12 | |
NM_013871 |
mitogen-activated protein kinase 12 (Mapk12), mRNA [NM_013871] |
KLA | .94 |
.86 |
.87 |
.81 |
.77 |
.68 |
.49 |
| ATP | .97 |
.83 |
.92 |
.90 |
.86 |
.90 |
.51 |
| KLA/ATP | .91 |
.89 |
.88 |
.85 |
1.12 |
1.14 |
.53 |
|
Mapk13 | |
NM_011950 |
mitogen-activated protein kinase 13 (Mapk13), mRNA [NM_011950] |
KLA | 1.22 |
1.21 |
1.35 |
1.26 |
1.24 |
1.13 |
1.01 |
| ATP | 1.08 |
1.00 |
1.20 |
1.20 |
1.13 |
1.22 |
1.39 |
| KLA/ATP | 1.22 |
1.27 |
1.30 |
1.30 |
1.21 |
1.11 |
1.47 |
|
Mapk14 | |
NM_011951 |
mitogen-activated protein kinase 14 (Mapk14), mRNA [NM_011951] |
KLA | .70 |
.70 |
.62 |
.54 |
.67 |
.88 |
1.11 |
| ATP | 1.03 |
.98 |
.87 |
.69 |
.48 |
.78 |
.66 |
| KLA/ATP | .74 |
.68 |
.52 |
.46 |
.38 |
.45 |
.62 |
|
Mapk3 | |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mapk8 | |
AK162915 |
adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] |
KLA | .94 |
.86 |
.80 |
.83 |
.77 |
.85 |
.83 |
| ATP | 1.08 |
1.12 |
.94 |
.80 |
.83 |
.71 |
.75 |
| KLA/ATP | .83 |
.81 |
.80 |
.74 |
.74 |
.75 |
.67 |
|
Mapk8 | |
AK163829 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] |
KLA | .65 |
.61 |
.66 |
.70 |
.90 |
1.02 |
1.03 |
| ATP | .99 |
.94 |
1.68 |
1.44 |
1.75 |
1.84 |
1.10 |
| KLA/ATP | .63 |
.67 |
1.11 |
1.00 |
2.01 |
1.68 |
1.15 |
|
Mapk8 | |
NM_016700 |
mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] |
KLA | .96 |
1.00 |
.94 |
.96 |
.94 |
.99 |
1.04 |
| ATP | 1.01 |
1.05 |
1.01 |
.99 |
1.03 |
.98 |
1.02 |
| KLA/ATP | .96 |
.97 |
.96 |
.97 |
.93 |
.94 |
.96 |
|
Mapk9 | |
NM_016961 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] |
KLA | 1.28 |
1.37 |
1.59 |
1.60 |
1.61 |
1.43 |
1.38 |
| ATP | 1.03 |
.99 |
.74 |
.71 |
.79 |
1.20 |
1.01 |
| KLA/ATP | 1.53 |
1.30 |
1.07 |
.99 |
.83 |
1.10 |
1.40 |
|
Mapk9 | |
NM_207692 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] |
KLA | 1.39 |
1.53 |
1.69 |
1.69 |
1.55 |
1.44 |
1.51 |
| ATP | .95 |
.92 |
.75 |
.85 |
.70 |
1.46 |
1.17 |
| KLA/ATP | 1.37 |
1.35 |
.99 |
1.18 |
.91 |
1.22 |
1.62 |
|
Mm.18787 9 | |
149250519 |
Unknown |
KLA | .98 |
.98 |
1.02 |
1.05 |
1.01 |
1.10 |
1.02 |
| ATP | 1.03 |
1.00 |
.98 |
1.02 |
1.02 |
1.04 |
.99 |
| KLA/ATP | .99 |
1.07 |
1.04 |
1.02 |
.94 |
.97 |
.93 |
|
Mm.21312 8 | |
141801344 |
Unknown |
KLA | .96 |
.95 |
.83 |
.77 |
.52 |
.99 |
1.32 |
| ATP | .80 |
.82 |
1.09 |
.80 |
.83 |
1.19 |
1.46 |
| KLA/ATP | .78 |
.92 |
.98 |
.62 |
.71 |
.94 |
1.41 |
|
Mm.24936 4 | |
133892283 |
Unknown |
KLA | 1.42 |
1.41 |
1.61 |
2.14 |
2.88 |
2.49 |
2.03 |
| ATP | .98 |
.98 |
.76 |
.77 |
1.09 |
1.23 |
1.28 |
| KLA/ATP | 1.32 |
1.32 |
1.07 |
1.12 |
1.38 |
1.85 |
1.95 |
|
Mm.25381 9 | |
118130676 |
Unknown |
KLA | 1.81 |
1.88 |
1.96 |
1.62 |
1.89 |
2.44 |
1.56 |
| ATP | .92 |
.91 |
1.24 |
1.01 |
1.16 |
2.06 |
1.95 |
| KLA/ATP | 1.62 |
1.86 |
1.86 |
1.41 |
1.89 |
2.37 |
1.97 |
|
Mm.25806 5 | |
148747407 |
Unknown |
KLA | 1.05 |
1.02 |
1.03 |
1.00 |
.99 |
1.05 |
.94 |
| ATP | .98 |
.98 |
1.03 |
1.02 |
.99 |
1.06 |
1.03 |
| KLA/ATP | 1.01 |
1.02 |
1.03 |
1.01 |
.96 |
.98 |
1.01 |
|
Mm.27970
| |
13994135 |
Unknown |
KLA | 1.06 |
1.11 |
1.16 |
1.07 |
1.11 |
1.08 |
.95 |
| ATP | 1.02 |
1.09 |
1.05 |
1.05 |
.94 |
1.16 |
1.32 |
| KLA/ATP | 1.10 |
1.19 |
1.11 |
1.04 |
1.08 |
1.02 |
1.33 |
|
Mm.33565 9 | |
160333365 |
Unknown |
KLA | 5.54 |
4.69 |
3.93 |
3.03 |
2.00 |
1.91 |
1.69 |
| ATP | .98 |
.81 |
1.01 |
.78 |
.68 |
1.71 |
1.10 |
| KLA/ATP | 5.05 |
4.44 |
5.07 |
2.38 |
1.34 |
1.88 |
2.00 |
|
Mm.38049
| |
118130391 |
Unknown |
KLA | .67 |
.65 |
.73 |
.92 |
.63 |
.81 |
.76 |
| ATP | .93 |
.92 |
1.08 |
.54 |
.45 |
1.48 |
1.56 |
| KLA/ATP | .57 |
.65 |
.98 |
.67 |
.44 |
.78 |
1.16 |
|
Mm.41274 5 | |
110681696 |
Unknown |
KLA | .97 |
1.07 |
1.11 |
1.07 |
1.38 |
1.63 |
1.35 |
| ATP | 1.06 |
1.09 |
1.05 |
1.29 |
1.04 |
.50 |
.56 |
| KLA/ATP | 1.11 |
1.12 |
1.04 |
1.11 |
.92 |
.83 |
.74 |
|
Mm.4387 | |
133892666 |
Unknown |
KLA | .85 |
.87 |
.85 |
.89 |
.77 |
.91 |
1.18 |
| ATP | 1.01 |
1.01 |
.87 |
1.07 |
.75 |
.86 |
.93 |
| KLA/ATP | .88 |
.86 |
.77 |
.81 |
.72 |
.91 |
.84 |
|
Mm.46002 4 | |
38348245 |
Unknown |
KLA | 1.22 |
1.25 |
1.25 |
1.19 |
1.22 |
1.47 |
1.14 |
| ATP | 1.03 |
.94 |
1.01 |
1.01 |
2.67 |
2.31 |
1.37 |
| KLA/ATP | 1.35 |
1.19 |
1.27 |
1.22 |
1.99 |
1.83 |
1.45 |
|
Mm.874 | |
6754317 |
Unknown |
KLA | 24.98 |
24.87 |
26.43 |
39.61 |
12.88 |
8.64 |
1.63 |
| ATP | 1.97 |
3.50 |
11.05 |
28.47 |
38.30 |
10.44 |
.65 |
| KLA/ATP | 23.45 |
29.37 |
58.52 |
51.77 |
30.64 |
14.61 |
8.63 |
|
Myd88 | |
NM_010851 |
myeloid differentiation primary response gene 88 (Myd88), mRNA [NM_010851] |
KLA | 3.35 |
3.51 |
3.91 |
4.13 |
4.13 |
3.62 |
2.53 |
| ATP | .99 |
.96 |
.79 |
.75 |
.93 |
2.15 |
1.60 |
| KLA/ATP | 3.37 |
3.52 |
3.52 |
3.48 |
2.81 |
3.03 |
3.33 |
|
Nfkb1 | |
BC050841 |
nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] |
KLA | 5.81 |
4.96 |
4.77 |
3.21 |
3.37 |
2.00 |
1.71 |
| ATP | 1.39 |
1.52 |
3.25 |
12.63 |
13.64 |
4.80 |
1.08 |
| KLA/ATP | 7.21 |
8.69 |
19.53 |
23.93 |
11.70 |
2.85 |
2.01 |
|
Nfkb1 | |
M57999 |
gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] |
KLA | 8.55 |
7.87 |
7.35 |
6.13 |
3.51 |
1.85 |
1.38 |
| ATP | .98 |
.96 |
1.21 |
3.06 |
5.29 |
4.67 |
.69 |
| KLA/ATP | 7.32 |
7.20 |
8.71 |
10.82 |
5.55 |
2.77 |
1.54 |
|
Nfkbia | |
NM_010907 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] |
KLA | 18.65 |
18.46 |
13.63 |
17.88 |
14.25 |
9.17 |
7.92 |
| ATP | .91 |
1.09 |
7.11 |
32.39 |
17.44 |
10.49 |
1.72 |
| KLA/ATP | 15.57 |
17.66 |
15.73 |
23.91 |
13.83 |
10.73 |
9.48 |
|
Nfkbib | |
NM_010908 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta (Nfkbib), mRNA [NM_010908] |
KLA | 4.63 |
4.69 |
4.36 |
4.27 |
4.23 |
2.52 |
2.17 |
| ATP | 1.11 |
1.22 |
1.55 |
4.23 |
4.93 |
3.66 |
1.76 |
| KLA/ATP | 4.71 |
5.41 |
4.58 |
7.08 |
6.20 |
4.73 |
4.11 |
|
Nos2 | |
NM_010927 |
nitric oxide synthase 2, inducible, macrophage (Nos2), mRNA [NM_010927] |
KLA | 13.50 |
16.36 |
25.65 |
23.25 |
24.78 |
15.99 |
6.48 |
| ATP | 1.03 |
1.03 |
1.48 |
1.66 |
1.65 |
5.55 |
1.70 |
| KLA/ATP | 16.01 |
17.41 |
19.06 |
25.50 |
20.84 |
29.92 |
29.80 |
|
Pdk1 | |
AK165090 |
2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330005M21 product:hypothetical protein, full insert sequence. [AK165090] |
KLA | .86 |
.77 |
.71 |
.67 |
.45 |
.29 |
.35 |
| ATP | 1.06 |
.88 |
1.21 |
.72 |
.60 |
.26 |
.15 |
| KLA/ATP | .81 |
.74 |
.97 |
.57 |
.51 |
.22 |
.09 |
|
Pdk1 | |
NM_172665 |
pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1), nuclear gene encoding mitochondrial protein, mRNA [NM_172665] |
KLA | .92 |
.94 |
.91 |
.79 |
.63 |
.46 |
.51 |
| ATP | .95 |
1.03 |
1.06 |
1.02 |
.63 |
.31 |
.37 |
| KLA/ATP | .88 |
.91 |
.91 |
.89 |
.62 |
.31 |
.27 |
|
Pik3ca | |
ENSMUST00000108243 |
ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] |
KLA | 1.07 |
1.01 |
.91 |
.90 |
.98 |
.96 |
.86 |
| ATP | 1.03 |
.87 |
1.12 |
.63 |
1.22 |
1.86 |
.60 |
| KLA/ATP | 1.05 |
.82 |
.91 |
.61 |
1.17 |
1.26 |
.63 |
|
Pik3ca | |
NM_008839 |
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] |
KLA | 1.15 |
1.11 |
1.05 |
.82 |
.99 |
1.03 |
1.27 |
| ATP | .98 |
1.00 |
.79 |
.75 |
.96 |
1.32 |
1.10 |
| KLA/ATP | 1.10 |
.98 |
.64 |
.72 |
.80 |
1.20 |
1.41 |
|
Pik3cb | |
NM_029094 |
phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] |
KLA | 1.06 |
1.06 |
1.03 |
.73 |
.68 |
.98 |
1.69 |
| ATP | 1.04 |
1.21 |
.95 |
1.02 |
.85 |
.93 |
1.73 |
| KLA/ATP | 1.15 |
1.27 |
.73 |
.83 |
.58 |
.81 |
1.81 |
|
Pik3cd | |
NM_008840 |
phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] |
KLA | 2.28 |
2.42 |
3.10 |
4.17 |
3.35 |
2.31 |
1.34 |
| ATP | 1.02 |
.91 |
.99 |
.63 |
.30 |
.67 |
.80 |
| KLA/ATP | 2.14 |
2.23 |
2.70 |
1.51 |
1.17 |
.85 |
.72 |
|
Pik3cd | |
U86587 |
phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] |
KLA | 2.21 |
2.24 |
3.71 |
3.17 |
3.67 |
2.66 |
1.48 |
| ATP | 1.00 |
1.03 |
.93 |
.96 |
.46 |
.75 |
.97 |
| KLA/ATP | 2.27 |
2.32 |
1.97 |
2.02 |
1.01 |
.99 |
.98 |
|
Pik3cg | |
NM_020272 |
phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] |
KLA | .53 |
.53 |
.61 |
.64 |
.97 |
.86 |
.79 |
| ATP | 1.01 |
1.13 |
.88 |
.89 |
.52 |
.53 |
.53 |
| KLA/ATP | .58 |
.53 |
.43 |
.60 |
.40 |
.43 |
.62 |
|
Pik3r1 | |
NM_001077495 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] |
KLA | 1.05 |
1.07 |
1.03 |
1.00 |
1.01 |
1.20 |
.85 |
| ATP | .97 |
1.02 |
1.48 |
1.42 |
1.76 |
1.33 |
1.23 |
| KLA/ATP | 1.11 |
1.12 |
1.06 |
1.17 |
1.24 |
.99 |
1.12 |
|
Pik3r2 | |
NM_008841 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] |
KLA | .50 |
.50 |
.48 |
.43 |
.46 |
.66 |
.75 |
| ATP | .78 |
.68 |
.45 |
.43 |
.28 |
.57 |
1.37 |
| KLA/ATP | .49 |
.38 |
.32 |
.33 |
.38 |
.67 |
1.10 |
|
Pik3r3 | |
NM_181585 |
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] |
KLA | 1.59 |
1.49 |
1.37 |
1.17 |
1.05 |
1.55 |
1.41 |
| ATP | 1.12 |
1.00 |
1.33 |
1.70 |
2.01 |
2.37 |
2.02 |
| KLA/ATP | 1.63 |
1.54 |
1.58 |
1.70 |
2.43 |
2.68 |
1.92 |
|
Pik3r5 | |
NM_177320 |
phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] |
KLA | 3.57 |
3.58 |
4.16 |
3.54 |
4.11 |
2.59 |
2.39 |
| ATP | 1.08 |
1.08 |
.93 |
1.67 |
3.11 |
1.88 |
1.34 |
| KLA/ATP | 3.91 |
3.70 |
3.30 |
3.80 |
2.70 |
2.04 |
3.00 |
|
Ppif | |
NM_134084 |
peptidylprolyl isomerase F (cyclophilin F) (Ppif), nuclear gene encoding mitochondrial protein, mRNA [NM_134084] |
KLA | 1.06 |
1.10 |
1.37 |
1.26 |
1.55 |
1.32 |
1.54 |
| ATP | 1.08 |
1.07 |
1.15 |
2.39 |
1.83 |
1.20 |
1.17 |
| KLA/ATP | 1.17 |
1.17 |
1.33 |
2.50 |
2.70 |
1.72 |
1.06 |
|
Rela | |
NM_009045 |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] |
KLA | 2.05 |
2.05 |
2.07 |
1.75 |
1.83 |
1.58 |
1.33 |
| ATP | 1.03 |
1.08 |
1.10 |
1.44 |
1.61 |
2.48 |
1.05 |
| KLA/ATP | 2.17 |
2.27 |
2.05 |
2.47 |
1.93 |
2.35 |
2.02 |
|
Socs1 | |
NM_009896 |
suppressor of cytokine signaling 1 (Socs1), mRNA [NM_009896] |
KLA | 27.36 |
22.16 |
20.64 |
23.08 |
17.74 |
21.71 |
10.12 |
| ATP | .91 |
.72 |
2.03 |
12.69 |
9.16 |
19.87 |
6.80 |
| KLA/ATP | 26.70 |
24.56 |
28.15 |
31.28 |
26.32 |
29.95 |
22.51 |
|
Stat1 | |
NM_009283 |
signal transducer and activator of transcription 1 (Stat1), mRNA [NM_009283] |
KLA | 2.90 |
2.72 |
3.00 |
3.64 |
4.58 |
6.51 |
5.58 |
| ATP | 1.01 |
.92 |
.89 |
.72 |
.51 |
2.22 |
3.07 |
| KLA/ATP | 2.73 |
2.65 |
2.34 |
1.95 |
1.99 |
4.70 |
8.66 |
|
Stat3 | |
NM_213659 |
signal transducer and activator of transcription 3 (Stat3), transcript variant 1, mRNA [NM_213659] |
KLA | 4.36 |
4.42 |
4.67 |
6.02 |
4.95 |
3.45 |
1.46 |
| ATP | 1.01 |
.97 |
1.07 |
1.17 |
2.47 |
4.04 |
1.47 |
| KLA/ATP | 4.02 |
4.57 |
6.65 |
6.51 |
7.06 |
7.39 |
3.61 |
|
Tgfb1 | |
NM_011577 |
transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] |
KLA | .87 |
.89 |
.90 |
.70 |
.83 |
.77 |
1.12 |
| ATP | 1.20 |
1.41 |
.80 |
1.49 |
1.11 |
.93 |
.99 |
| KLA/ATP | 1.10 |
1.20 |
.53 |
1.05 |
.66 |
.85 |
.90 |
|
Tgfb2 | |
NM_009367 |
transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] |
KLA | 1.01 |
.91 |
.98 |
.98 |
.92 |
1.19 |
.96 |
| ATP | .99 |
1.03 |
1.00 |
1.02 |
.99 |
1.07 |
.93 |
| KLA/ATP | 1.02 |
.99 |
1.03 |
.98 |
1.04 |
1.06 |
.96 |
|
Tgfb3 | |
NM_009368 |
transforming growth factor, beta 3 (Tgfb3), mRNA [NM_009368] |
KLA | .67 |
.64 |
.58 |
.56 |
.49 |
.52 |
.61 |
| ATP | .90 |
.92 |
1.33 |
1.08 |
.78 |
.65 |
.74 |
| KLA/ATP | .58 |
.60 |
.74 |
.61 |
.76 |
1.36 |
1.51 |
|
Tlr2 | |
NM_011905 |
toll-like receptor 2 (Tlr2), mRNA [NM_011905] |
KLA | 13.65 |
11.82 |
8.87 |
7.95 |
4.67 |
2.78 |
2.33 |
| ATP | 1.06 |
1.24 |
2.76 |
6.28 |
11.55 |
13.82 |
.67 |
| KLA/ATP | 13.11 |
12.91 |
14.48 |
13.84 |
14.18 |
11.14 |
2.78 |
|
Tlr4 | |
NM_021297 |
toll-like receptor 4 (Tlr4), mRNA [NM_021297] |
KLA | .69 |
.61 |
.75 |
.94 |
.64 |
.81 |
.73 |
| ATP | .95 |
.90 |
1.12 |
.56 |
.47 |
1.51 |
1.53 |
| KLA/ATP | .57 |
.62 |
1.01 |
.64 |
.39 |
.73 |
1.13 |
|
Tnf | |
NM_013693 |
tumor necrosis factor (Tnf), mRNA [NM_013693] |
KLA | 13.35 |
12.76 |
10.71 |
9.03 |
10.64 |
7.39 |
8.32 |
| ATP | 2.01 |
2.48 |
8.27 |
19.20 |
9.72 |
4.09 |
1.49 |
| KLA/ATP | 12.72 |
15.76 |
12.73 |
17.34 |
5.10 |
3.61 |
6.07 |
|
Tnfrsf1a
| |
NM_011609 |
tumor necrosis factor receptor superfamily, member 1a (Tnfrsf1a), mRNA [NM_011609] |
KLA | 1.74 |
1.71 |
1.90 |
2.16 |
1.95 |
1.74 |
1.16 |
| ATP | .95 |
.83 |
.55 |
.41 |
.41 |
1.55 |
1.32 |
| KLA/ATP | 1.58 |
1.49 |
1.19 |
1.03 |
.98 |
2.02 |
2.10 |
|
Traf6 | |
NM_009424 |
Tnf receptor-associated factor 6 (Traf6), mRNA [NM_009424] |
KLA | 1.19 |
1.28 |
1.34 |
1.20 |
1.23 |
1.23 |
1.28 |
| ATP | 1.06 |
1.12 |
.92 |
1.15 |
2.46 |
1.84 |
1.40 |
| KLA/ATP | 1.32 |
1.37 |
.89 |
1.16 |
1.45 |
1.49 |
1.46 |
|
Tyk2 | |
NM_018793 |
tyrosine kinase 2 (Tyk2), mRNA [NM_018793] |
KLA | 2.91 |
2.95 |
3.42 |
3.26 |
3.85 |
2.35 |
1.42 |
| ATP | 1.09 |
1.01 |
.68 |
.64 |
.59 |
.86 |
1.10 |
| KLA/ATP | 2.95 |
3.04 |
2.23 |
1.82 |
1.24 |
1.27 |
2.09 |
|
Xiap | |
NM_009688 |
X-linked inhibitor of apoptosis (Xiap), mRNA [NM_009688] |
KLA | 1.61 |
1.63 |
1.62 |
1.52 |
1.34 |
1.27 |
1.11 |
| ATP | 1.03 |
1.01 |
.99 |
.96 |
.88 |
1.19 |
1.25 |
| KLA/ATP | 1.64 |
1.63 |
1.54 |
1.33 |
1.08 |
1.19 |
1.72 |
|